





WHO ARE THE MEMBERS IN NEWMEDS?

EFPIA companies

H Lundbeck A/S, AstraZeneca AB, Eli Lilly and Company Ltd, Janssen Pharmaceutica NV, Novartis Pharma AG, Orion Corporation, Pfizer Limited, F. Hoffmann-La Roche AG, Institut de Recherches Servier

Universities

King's College London (UK), Karolinska Institutet (*Sweden*), The University of Cambridge (UK), Central Institute of Mental Health (*Germany*), CSIC (*Spain*), The University of Manchester (UK), Bar Ilan University (*Israel*)

SME's Psynova Neurotech Ltd (UK), deCODE genetics (Iceland), GABO:mi (Germany)

WHO ARE THE KEY CONTACTS IN NEWMEDS?

Coordinator

H Lundbeck A/S, Copenhagen, Dr Tine Bryan Stensbøl

Leader of the Managing Entity King's College London, London, Prof Shitij Kapur

Project Office GABO:milliarium mbH & Co. KG, Munich, Kathrin Stoller

www.newmeds-europe.com



NEWMEDS

Novel MEthods leading to NeW MEdications in Depression and Schizophrenia

EVVMEDS



WHAT IS NEWMEDS?

NEWMEDS – Novel Methods leading to New Medications in Depression and Schizophrenia – is an international consortium of scientists that has launched one of the largest ever research academic-industry collaboration projects to find new methods for the development of drugs for schizophrenia and depression.

WHAT IS THE INTENTION OF NEWMEDS?

NEWMEDS brings together top scientists from academic institutions with a wide range of expertise, and partners them with nearly all major biopharmaceutical companies. The project will focus on developing new animal models which use brain recording and behavioural tests to identify innovative and effective drugs for schizophrenia. The project will develop standardised paradigms, acquisition and analysis techniques to apply brain imaging, especially fMRI and PET imaging to drug development. It will examine how new genetic findings (duplication and deletion or changes in genes) influence the response to various drugs and whether this information can be used to choose the right drug for the right patient. And finally, it will try and develop new approaches for shorter and more efficient trials of new medication – trials that may require fewer patients and give faster results.

WHO SUPPORTS NEWMEDS?

NEWMEDS is funded by the Innovative Medicines Initiative (IMI), a unique large scale public-private partnership between the European Union (represented by the European Commission) and the pharmaceutical industry (represented by the European Federation of Pharmaceutical Industries and Associations, EFPIA).

IMI aims to put Europe at the forefront of biopharmaceutical innovation and to support more efficient discovery and development of better medicines for patients. www.imi.europa.eu



nnovative Medicines Initiative



KEY DATA FOR NEWMEDS

Start date:	1 September 2009
Runtime:	5 years
Structure:	11 Workpackages
Clusters:	System based animal models Translational Technology Patient Stratification